https://orcid.org/0000-0001-7650-2582
References
- Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 2023;82:3–18.
- Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 2022;386:316–26.
- Campochiaro C, Farina N, Tomelleri A, De Luca G, Baldissera E, Cavalli G, et al. Drug retention rates of biological agents in adult onset Still’s disease. Semin Arthritis Rheum 2021;51:1–6.
- Ebina K, Etani Y, Maeda Y, Okita Y, Hirao M, Yamamoto W, et al. Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study. RMD Open 2023;9:e003160.
- Lauper K, Iudici M, Mongin D, Bergstra SA, Choquette D, Codreanu C, et al. Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the “JAK-pot” collaboration. Ann Rheum Dis 2022;81:1358–66.
- Biggioggero M, Gremese E, Bugatti S, Manfredi A, Parisi S, Bazzani C, et al. POS0858 the long-term retention rate of JAK inhibitors in rheumatoid arthritis: data from the national Italian registry GISEA. Ann Rheum Dis 2023;82:733–4.
- Scheepers L, Jones G. AB0414 drug persistence on Janus kinase (JAK) inhibitors compared to biologic DMARDs in patients with rheumatoid arthritis: retrospective study in the Australian population. Ann Rheum Dis 2022;81:1335–1335.
- Ebina K, Hirano T, Maeda Y, Yamamoto W, Hashimoto M, Murata K, et al. Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study. Sci Rep 2022;12:134.
- Fornaro M, Caporali R, Montecucco C, Cauli A, Conti F, Chimenti MS, et al. POS0852 real life data of filgotinib in rheumatoid arthritis patients: data from Italian GISEA registry. Ann Rheum Dis 2023;82:728–9.
- European Medicines Agency. Janus kinase inhibitors (JAKi). 2023. Available from: https://www.ema.europa.eu/en/medicines/human/referrals/janus-kinase-inhibitors-jaki
- Takabayashi K, Ando F, Ikeda K, Fujita S, Nakajima H, Hanaoka H, et al. Trend in prescription and treatment retention of molecular-targeted drugs in 121,131 Japanese patients with rheumatoid arthritis: a population-based real-world study. Mod Rheumatol 2022;32:857–65.
- Finckh A, Tellenbach C, Herzog L, Scherer A, Moeller B, Ciurea A, et al. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland. RMD Open 2020;6:e001174.
- González Mazarío R, Fragío Gil JJ, Ivorra Cortés J, Grau García E, Cañada Martínez AJ, González Puig L, et al. Real-world effectiveness and safety of JAK inhibitors in rheumatoid arthritis: a single-centre study. Reumatol Clin 2022;18:523–30.
- Tomelleri A, Benanti G, Cariddi A, Calvisi SL, Baldissera E, Boffini N, et al. The impact of 2023 EMA recommendations on patients treated with JAK inhibitors: real-life experience from a prospective monocentric cohort. Rheumatology (Oxford) 2023;18:kead395.